Transcend Capital Advisors LLC Lowers Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Transcend Capital Advisors LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,636 shares of the life sciences company’s stock after selling 307 shares during the period. Transcend Capital Advisors LLC’s holdings in Illumina were worth $620,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc lifted its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the 4th quarter worth $32,000. TD Private Client Wealth LLC lifted its stake in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares during the last quarter. Finally, Private Trust Co. NA lifted its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $94.20 on Friday. The company has a market capitalization of $14.92 billion, a P/E ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 12-month low of $93.50 and a 12-month high of $156.66. The business’s 50 day moving average is $127.98 and its two-hundred day moving average is $134.13. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several analyst reports. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and decreased their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. increased their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. UBS Group increased their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird increased their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.